Sharemaestro Newsreel

Maxim Group Maintains Femasys(FEMY.US) With Buy Rating, Cuts Target Price to $10

Maxim Group has reiterated its Buy rating on Femasys (FEMY.US) but has adjusted its price target downwards to $10. This indicates continued confidence in the company's prospects despite a revised valuation.

Cadian Capital discloses 7.5% SI-BONE (SIBN) ownership in Schedule 13G filing

Cadian Capital Management, LP, along with Cadian Capital Management GP, LLC, and Eric Bannasch, has reported a 7.5% passive ownership stake in SI-BONE, Inc. (SIBN) through a Schedule 13G filing. As of June 30, 2026, the reporting persons beneficially owned 3,347,574 shares of SI-BONE …

Beyond Air Sticks to Revenue Targets as LungFit PH Gen II FDA Decision Nears

Beyond Air reported flat quarterly revenue of $1.8 million but reaffirmed its 2026 and 2027 revenue guidance, signaling confidence in future growth driven by an expanding commercial pipeline. The company is awaiting an FDA decision for its second-generation LungFit PH system, now anticipated in …

Precigen (NASDAQ:PGEN) Trading Down 5.5% - What's Next?

Precigen (NASDAQ:PGEN) saw its shares drop by 5.5% despite reporting stronger-than-expected quarterly results, with EPS of $0.05 against an estimated loss of $0.01, and revenue soaring by 6,322.7% year-over-year to $54.98 million. The biotechnology company maintains a "Moderate Buy" consensus rating with an average …

Omada Health (OMDA): American Century group reports 6.2% stake in Schedule 13G

American Century Investment Management, Inc., American Century Companies, Inc., and Stowers Institute for Medical Research have collectively reported a 6.2% beneficial ownership stake in Omada Health, Inc. (OMDA) common stock as of June 30, 2026, through a Schedule 13G filing. The group beneficially owns …

Innate Pharma Secures €30M, Extends Cash Runway Into 2028

Innate Pharma has secured €30 million in equity financing, which, combined with a potential €75 million upfront payment from its partnership with Sobi, is expected to extend its cash runway into the first quarter of 2028. This funding will support the development of lacutamab, …

Tactile Systems Technology (TCMD) investor discloses 7% equity stake

Cadian Capital entities and Eric Bannasch have disclosed a 7.0% beneficial ownership stake in Tactile Systems Technology (TCMD), totaling 1,576,940 shares of common stock as of June 30, 2026. This ownership is managed through Cadian Master Fund L.P. and Cadian Opportunities Master Fund LP, …

SDGR Assumed by UBS -- Price Target Raised to $19.00

UBS has assumed coverage on Schrodinger (SDGR), raising its price target from $13.00 to $19.00, while maintaining a Neutral rating. GuruFocus indicates SDGR is currently undervalued by 29.0% with a GF Value™ of $25.03 and has a moderately favorable GF Score™ of 73/100, though …

Nyxoah (NASDAQ: NYXH) investors report 11.0M-share, 9.9% beneficial stake

CVI Investments, Inc. and Heights Capital Management, Inc. have reported a beneficial ownership of 11,014,861 Ordinary Shares in Nyxoah SA (NASDAQ: NYXH), which represents a 9.9% stake in the company. This holding includes 828,803 existing shares and additional shares convertible from notes, subject to …

AWM Investment Company reports 11.8% 908 Devices (MASS) ownership through Special Situations funds

AWM Investment Company has reported an 11.8% ownership stake in 908 Devices (MASS) through its Special Situations funds, as detailed in a recent SCHEDULE 13G/A SEC filing. This beneficial ownership amounts to 4,879,773 shares, with AWM holding sole voting and dispositive power over these …

ARK Investment Management (MASS) reports 2.0M-share, 5.32% holding in 908 Devices

ARK Investment Management LLC and its CEO/CIO, Catherine D. Wood, have reported a beneficial ownership of 2,027,920 shares of 908 Devices Inc. common stock, which represents 5.32% of the outstanding class. The disclosure, filed as a Schedule 13G/A, indicates that ARK has sole voting …

CervoMed (CRVO) holders CVI and Heights report 0% stake in amended filing

CVI Investments, Inc. and Heights Capital Management, Inc. have filed an amended Schedule 13G/A for CervoMed Inc. (CRVO), reporting a 0% beneficial ownership in the company. This filing indicates that both entities collectively hold no shares and possess no voting or dispositive power over …

ARK reports 9.59% stake in Pacific Biosciences (PACB)

ARK Investment Management LLC and Catherine D. Wood have reported a beneficial ownership of 9.59% in Pacific Biosciences of California, Inc. (PACB), amounting to 29,781,416 shares. This disclosure, made via a SCHEDULE 13G/A filing, details their sole and shared voting and dispositive powers over …

Beam Therapeutics (BEAM): ARK Investment and Cathie Wood report 9.95% stake

ARK Investment Management LLC and Cathie Wood have reported a beneficial ownership of 9.95% in Beam Therapeutics Inc. (BEAM), totaling 10,234,862 shares. This disclosure, filed via a SCHEDULE 13G/A, indicates that ARK has significant voting and dispositive power over these shares. The filing also …

Polyrizon Ltd. (PLRZ): MMCAP group discloses 9.6% beneficial stake

MMCAP International Inc. SPC and MM Asset Management Inc. have disclosed a 9.6% beneficial stake in Polyrizon Ltd. (PLRZ), owning 199,470 ordinary shares. This information was reported in an amended Schedule 13G filing, indicating shared voting and dispositive power over these shares. The filing …

Teleflex (TFX) Stock Looks Undervalued On Cash Flow But Overvalued On Sales

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Teleflex stock has rebounded in the short term yet still sits far below its level of five years ago, while the valuation checks send …

Bristol Myers Squibb (BMY) Wins FDA Approval, Is The Stock Fully Priced?

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Bristol Myers Squibb (BMY) is back in focus after the FDA granted accelerated approval for ZENBEXUS in a multiple myeloma combination regimen, introducing …

Candel Therapeutics (NASDAQ:CADL) Stock Price Expected to Rise, Bank of America Analyst Says

Price-Driven Insight from (CRBP) for Rule-Based Strategy

This article provides a price-driven insight for Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), outlining near-term and mid-term strong sentiment but a weak long-term outlook. It details specific trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis and support/resistance …

Bernstein Lifts Regeneron Price Target to $756, Stays on Sidelines

Bernstein has raised its price target for Regeneron Pharmaceuticals to $756 from $753, while maintaining a Market Perform rating, indicating a slightly more positive near-term outlook but not a fundamental shift in its investment thesis. This new target remains below the Wall Street consensus …

OSR Health (OSRH) cuts losses but faces sharp revenue drop and tight cash

What Does Stryker (SYK) Q1 Growth Mean If Costs Are Still Pressuring Earnings?

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Stryker (NYSE:SYK) reported strong first quarter growth, supported by underlying demand and a recovery from a prior cyber incident. The company highlighted organic growth across …

SS Innovations International (SSII) Reports Record Q2 Revenue of $13.9M, Up 39.4%

SS Innovations International (SSII) announced record second-quarter 2026 revenue of $13.9 million, a 39.4% increase year-over-year, driven by a 30.4% rise in SSi Mantra surgical robotic system installations. The company reported a gross profit of $7.1 million and a cumulative installed base of 224 …

HTFL Maintained by Morgan Stanley -- Price Target Raised to $40.

Why Eton Pharmaceuticals Is Top of the Class Today

Key Points Eton Pharmaceuticals beat on both top and bottom lines last night. Management is licensing a new drug, and raising guidance through the end of 2026.10 stocks we like better than Eton Pharmaceuticals › Eton Pharmaceuticals (NASDAQ: ETON) stock soared 41.9% through 2:15 …

Zoetis: The Growth Story Has Broken, But The Valuation Finally Makes Sense (NYSE:ZTS)

Bleichroeder LP Discloses Investment at MDxHealth SA with 33.2% Stake

Bleichroeder LP has disclosed a 33.2% stake in MDxHealth SA after purchasing 24,229,074 shares in a direct offering for $0.454 per share. This investment gives Bleichroeder significant influence and is subject to a 90-day lock-up period. The firm stated its intent for portfolio purposes …

Gilead Sciences (GILD) Could Be 8% Overvalued As AI Deal And Q2 Results Lift Shares

Gilead Sciences (GILD) is gaining investor attention due to a new AI collaboration with Nucleai and positive Q2 results, though some analyses suggest it might be overvalued by about 8%. The company is transitioning into a multi-platform biopharma, but differing valuation models present varied …

Citius Pharmaceuticals (CTXR) holders report 3.0M-share, 9.9% beneficial stake

CVI Investments, Inc. and Heights Capital Management, Inc. have reported a beneficial ownership of 3,008,529 common shares in Citius Pharmaceuticals (CTXR), which represents a 9.9% stake. This position primarily consists of shares issuable upon the exercise of warrants, subject to beneficial ownership limits of …

UFP Technologies (NASDAQ: UFPT) insider plans sale of 2,349 shares

UFP Technologies (NASDAQ: UFPT) has filed a Form 144 to register the planned sale of 2,349 shares of common stock through Merrill Lynch on or after August 14, 2026. The shares have an aggregate market value of $625,145.67 and represent a small fraction of …

American Century group reports 5.4% Emergent BioSolutions (EBS) ownership on Schedule 13G

American Century ETF Trust and its affiliates, including American Century Investment Management, Inc., American Century Companies, Inc., and the Stowers Institute for Medical Research, have reported passive ownership stakes in Emergent BioSolutions Inc. (EBS) common stock via a Schedule 13G filing. The ETF Trust …

Assembly Biosciences (NASDAQ:ASMB) Trading Up 8.2% on Strong Earnings

Assembly Biosciences (NASDAQ:ASMB) saw its shares rise by 8.2% after reporting better-than-expected quarterly earnings, with a loss of $0.20 per share against an anticipated $0.72 loss and revenue of $13.37 million surpassing estimates of $8.60 million. Analysts have a "Moderate Buy" consensus rating with …

Goldman Sachs Group (TNGX) discloses 6.0% beneficial stake in Tango Therapeutics

The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have disclosed a 6.0% beneficial ownership stake in Tango Therapeutics, Inc. (TNGX) through a Schedule 13G filing. This holding amounts to 9,742,402.80 shares and signifies shared voting and dispositive power over …

Twist Bioscience (TWST): ARK Investment Management reports 4.55M-share, 7.31% stake

ARK Investment Management LLC and its founder Catherine D. Wood have reported a beneficial ownership of 4,549,803 shares of Twist Bioscience Corp (TWST) common stock, representing 7.31% of the company's class. The filing, a Schedule 13G/A, indicates that ARK has sole voting power over …

Will Pennant’s Higher 2026 Guidance and Tucson Acquisition Change Pennant Group's (PNTG) Narrative

The Pennant Group (PNTG) reported strong Q2 2026 results with increased sales and net income, along with higher 2026 revenue guidance of US$1.17 billion to US$1.19 billion. The company also expanded its senior living portfolio by acquiring the River Centre Assisted Living community in …

Heartflow, Inc. Stock 12‑Month Price Target Raised to $43.5, Implies 40% Upside

Heartflow, Inc.'s stock 12-month price target has been increased to $43.5 from $36.62, representing a 40% potential upside based on its closing price on August 13. This revised target comes from estimates by 8 analysts, with forecasts ranging from $39 to $45 per share. …